Beyond The T/C Ratio: Old And New Anticancer Activity Scores In Vivo

References

• Bissery MC, Guénard D, Guéritte-Voegelein F, et al. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991;51:4845–4852.1680023
   PubMed Web of Science ®Google Scholar
• Schabel FM, Griswold DP, Laster WR, et al. Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther Part Chemother Toxicol Metab Inhib. 1977;1:411–435.
   Web of Science ®Google Scholar
• Skipper HE, Schmidt LH. A manual on quantitative drug evaluation in experimental tumor systems. I. Background, description of criteria, and presentation of quantitative therapeutic data on various classes of drugs obtained in diverse experimental tumor systems. Cancer Chemother Rep. 1962;17:1–143.13913647
   PubMedGoogle Scholar
• Wilcox WS, Griswold DP, Laster WR, et al. Experimental evaluation of potenital anticancer agents. XVII. Kinetics of growth and regression after treatment of certain solid tumors. Cancer Chemother Rep. 1965;47:27–39.5829426
   PubMedGoogle Scholar
• Dethlefsen LA, ed. Cell Cycle Effects of Drugs. Oxford: Pergamon Press; 1986.
   Google Scholar
• Mauro F, Spanò M, Teodori L, et al. Cell cycle and effect of antineoplastic drugs: facts and pitfalls. Prog Clin Biol Res. 1983;132C:199–209.6634772
   PubMedGoogle Scholar
• Romano M, Frapolli R, Zangarini M, et al. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104). Int J Cancer. 2013;133:2024–2033. doi:10.1002/ijc.2821323588839
   PubMed Web of Science ®Google Scholar
• Lupi M, Matera G, Natoli C, Colombo V, Ubezio P. The contribution of p53 in the dynamics of cell cycle response to DNA damage interpreted by a mathematical model. Cell Cycle 2007;6:943–950. doi:10.4161/cc.6.8.410317387280
   PubMed Web of Science ®Google Scholar
• Ubezio P, Lupi M, Branduardi D, et al. Quantitative assessment of the complex dynamics of G1, S, and G2-M checkpoint activities. Cancer Res. 2009;69:5234–5240. doi:10.1158/0008-5472.CAN-08-366019509236
   PubMed Web of Science ®Google Scholar
• Lupi M, Cappella P, Matera G, Natoli C, Ubezio P. Interpreting cell cycle effects of drugs: the case of melphalan. Cancer Chemother Pharmacol. 2006;57:443–457. doi:10.1007/s00280-005-0044-116195878
   PubMed Web of Science ®Google Scholar
• Lupi M, Matera G, Branduardi D, et al. Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach. Cancer Res. 2004;64:2825–2832. doi:10.1158/0008-5472.CAN-03-381015087399
   PubMed Web of Science ®Google Scholar
• Ubezio P, Falcetta F, Carrassa L, Lupi M. Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer. Oncotarget. 2016;7:15492–15506. doi:10.18632/oncotarget.v7i1326909860
   PubMedGoogle Scholar
• Falcetta F, Lupi M, Colombo V, Ubezio P, Tucker-Kellogg G. Dynamic rendering of the heterogeneous cell response to anticancer treatments. PLoS Comput Biol. 2013;9:e1003293. doi:10.1371/journal.pcbi.100329324146610
   PubMed Web of Science ®Google Scholar
• Forrester HB, Albright N, Ling CC, Dewey WC. Computerized video time-lapse analysis of apoptosis of REC:myc cells X-irradiated in different phases of the cell cycle. Radiat Res. 2000;154:625–639. doi:10.1667/0033-7587(2000)154[0625:CVTLAO]2.0.CO;211096419
   PubMed Web of Science ®Google Scholar
• Forrester HB, Vidair CA, Albright N, et al. Using computerized video time lapse for quantifying cell death of X-irradiated rat embryo cells transfected with c-myc or c-Ha-ras. Cancer Res. 1999;59:931–939.10029087
   PubMed Web of Science ®Google Scholar
• Lee F, Weinmann R. Animal cancer models in anticancer drug discovery and development In: Azmi A, Mohammad RM, editors. Mouse Models of Human Blood Cancers. New York: Springer; 2008:245–258.
   Google Scholar
• Zhao Y-Z, Lu C-T, Zhou Z-C, et al. Enhancing chemotherapeutic drug inhibition on tumor growth by ultrasound: an in vivo experiment. J Drug Target. 2011;19:154–160. doi:10.3109/1061186100380183420429773
   PubMed Web of Science ®Google Scholar
• Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6:813–823. doi:10.1038/nrc195116990858
   PubMed Web of Science ®Google Scholar
• Wong H, Choo EF, Alicke B, et al. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res. 2012;18:3846–3855. doi:10.1158/1078-0432.CCR-12-073822648270
   PubMed Web of Science ®Google Scholar
• Wong H, Vernillet L, Peterson A, et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res. 2012;18:3090–3099. doi:10.1158/1078-0432.CCR-12-044522496205
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007;49:928–940. doi:10.1002/pbc.2107817066459
   PubMed Web of Science ®Google Scholar
• Cohen AA, Geva-Zatorsky N, Eden E, Page DC. Dynamic proteomics of individual cancer cells in response to a drug. Science. 2008;322:1511–1516. doi:10.1126/science.116634019023046
   PubMed Web of Science ®Google Scholar
• Toettcher JE, Loewer A, Ostheimer GJ, Yaffe MB, Tidor B, Lahav G. Distinct mechanisms act in concert to mediate cell cycle arrest. Proc Natl Acad Sci U S A. 2009;106:785–790. doi:10.1073/pnas.080619610619139404
   PubMed Web of Science ®Google Scholar
• Falcetta F, Bizzaro F, D’Agostini E, Bani MR, Giavazzi R, Ubezio P. Modeling cytostatic and cytotoxic responses to new treatment regimens for ovarian cancer. Cancer Res. 2017;77:6759–6769. doi:10.1158/0008-5472.CAN-17-109928951463
   PubMed Web of Science ®Google Scholar
• Bizzaro F, Falcetta F, D’Agostini E, et al. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab. Int J Cancer. 2018;143(9):2187–2199. doi:10.1002/ijc.31596
   PubMed Web of Science ®Google Scholar